Investigational drug · Phase 3
Pralurbactam
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hospital-acquired Bacterial Pneumonia (HABP), Ventilator-associated Bacterial Pneumonia (VABP), Complicated Intra-abdominal Infection (cIAI).
Phase 3Last checked: Nov 19, 2026Latest source record: Feb 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
3
Any phase or sponsor naming "Pralurbactam"
First trial start
2024
Oct 31, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Pralurbactam", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hospital-acquired Bacterial Pneumonia (HABP)
- Ventilator-associated Bacterial Pneumonia (VABP)
- Complicated Intra-abdominal Infection (cIAI)
- Complicated Urinary Tract Infection (cUTI)
- Bloodstream Infection (BSI)
- Intra-abdominal Infections
- Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia
Approved drugs for the same conditions: Urinary tract infection · Pneumonia · Infectious disease and vaccines · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "Pralurbactam" as an intervention, largest first.
- Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in CIAIPivotal-lookingNot yet recruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT06633718 · 786 participants (planned) · Start Oct 31, 2024 · Primary completion May 30, 2027
Drug: Meropenem and Pralurbactam; Saline and 2 more · For: Intra-abdominal Infections
Sites: Hangzhou, China
- A Study to Evaluate the Efficacy and Safety of Meropenem and Pralurbactam in HABP/VABPPivotal-lookingRecruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT07327619 · 420 participants (planned) · Start Jan 22, 2026 · Primary completion Jun 2028
Drug: Meropenem and Pralurbactam; Ceftazidime-avibactam · For: Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia
Sites: Huaihua, China
- Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae InfectionsPivotal-lookingRecruiting
Qilu Pharmaceutical Co., Ltd.Industry
NCT07089186 · 80 participants (planned) · Start Apr 12, 2025 · Primary completion Dec 2026
Drug: Meropenem and Pralurbactam; Best Available Therapy (e.g., colistin, meropenem, tegecycline, amikacinceftezidime-avibatam) · For: Hospital-acquired Bacterial Pneumonia (HABP); Ventilator-associated Bacterial Pneumonia (VABP); Complicated Intra-abdominal Infection (cIAI) and 2 more
Sites: Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
- Pharmacokinetic/pharma-codynamic study of pralurbactam (FL058) combined with meropenem in a neutropenic murine thigh infection model.
Huang Z, Li W, Zhang R, et al. · Front Microbiol 2024
Also in development for Hospital-acquired Bacterial Pneumonia (HABP)
- HRS-8427Phase 32 trials
Jiangsu HengRui Medicine Co., Ltd. · Complicated Urinary Tract Infection(cUTI), Including Acute Pyelonephritis(AP), Hospital-acquired Bacterial Pneumonia (HABP), Ventilator-associated Bacterial Pneumonia (VABP)
- YK-1169Phase 31 trial
Nanjing Yoko Biomedical Co., Ltd. · Hospital-acquired Bacterial Pneumonia (HABP), Ventilator-associated Bacterial Pneumonia (VABP)
- ASK0912Phase 21 trial
Jiangsu Aosaikang Pharmaceutical Co., Ltd. · Ventilator-associated Bacterial Pneumonia (VABP), Hospital-acquired Bacterial Pneumonia (HABP)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.